替芬泰片在健康人体的耐受性及药代动力学分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (53 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the tolerance and pharmacokinetics of Tefentai Tablets in healthy volunteers. Methods In this study,a randomized,double-blind method was used to study 26 healthy volunteers from January to June 2017,all patients were given 300 and 600 mg of Tefentanil,two doses of which were given single or multiple times,once a day for multiple times,7 days in a row,in which the drug elution cycle was 2 weeks.The pharmacokinetic parameters (the highest blood concentration [Cmax],the lowest blood concentration [Cmin],the average blood concentration[Cavg],the curve area of blood concentration over a period of time [AUC0-t],the infinite curve area of blood concentration[AUC0-∞] and accumulation index) were measured by high performance liquid chromatography at different time points.Pharmacokinetic parameters,high performance liquid chromatography characteristics and related adverse reactions were analyzed. Results The peak time (Tmax) was (1.02±0.13) h,and the half-life (t1/2) was (3.08±0.09) h after taking different doses of Tifentai Tablets for many times in healthy volunteers.The Tmaxof M8 was (3.05±0.07) h and t1/2was(9.56±0.67) h;The Tmaxof M9 was (4.11±0.15) h and T1/2was (6.17±0.21) h.At the dosage of 300 mg,there were no significant differences in Cmax,Cmin,Cavg,AUC0-t,AUC0-∞and accumulation index between multiple and single administration of Tifental (P>0.05).AUC0-tand AUC0-∞in multiple administration of metabolite N-benzoyl-O-(dimethylaminoethyl)-L-tyrosine (M8) and metabolite N-benzoyl-L-tyrosine-o-(N-oxidation-dimethylaminoethyl) - L-tyrosine(M9) were significantly higher than those of single administration (P<0.05).Cmaxof M9 multiple administration was higher than that of single administration,the difference was statistically significant (P<0.05).At the dosage of 600 mg,Cmaxin Tifental of multiple administration was higher than that of single administration,the difference was statistically significant (P<0.05).There were no significant differences in Cmin,Cavg,AUC0-t,AUC0-∞,accumulation index between multiple and single administration of Tifental (P>0.05).Cmaxand AUC0-tin multiple administration of M8 and M9 were significantly higher than that of single administration,the differences were statistically significant (P<0.05).The AUC0-∞of M9 multiple administration was higher than that of single administration,the difference was statistically significant (P<0.05).At the dose of 600 mg,repeated administration increased Cmax of Tifental,but had no significant effect on AUC0-∞of its exposure.The Cmaxof metabolites M8 and M9 increased,and the exposure of AUC0-∞increased.After several times of oral administration (doses of 300 and 600 mg) of Tifentai Tablets to healthy volunteers,a case of adverse event with foreign body sensation occurred in one volunteer at the dose of 600 mg,which was determined to be unrelated to the drug,and no volunteer withdrew from the trial due to adverse event. Conclusion Tifentai Tablets 600 mg dose not show obvious accumulation effect and high safety,in order to obtain better antiviral effect,it is suggested that the daily reference dose be 600 mg.

Key words： Tifentail Tablets Healthy volunteers Adverse reactions Pharmacokinetics

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Hong
	LI Jie
	WU Yu-chun
	CHENG Nan
	CHEN Hua-rong
	WU Gui-hui

Cite this article:

LIANG Hong,LI Jie,WU Yu-chun, et al. Analysis the tolerance and pharmacokinetics of Tefentai Tablets in healthy volunteers[J]. 中国当代医药, 2020, 27(2): 4-8.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I2/4

[1]	梁吉.浅谈我国乙型肝炎现状与防治对策[J].世界最新医学信息文摘，2019，19（18）：207，210.
[2]	焦娇，郭意男，章国君，等.乙肝肝硬化进展原发性肝癌的危险因素研究[J].预防医学，2019，31（4）：363-366，370.
[3]	李翠萍.慢性乙型肝炎的诊治进展[J].基层医学论坛，2019，23（11）：1583-1585.
[4]	王超，林松斌，许天奖，等.乙肝病毒基因分型与原发性肝癌关系研究[J].中外医学研究，2019，17（8）：3-5.
[5]	苗英霞.超敏HBVDNA在慢性乙型病毒性肝炎中的临床价值研究[D].青岛：青岛大学，2018.
[6]	陈洪涛，何桂蓉，杨智，等.核苷（酸）类药物治疗慢性乙型肝炎的耐药突变分析[J].新发传染病电子杂志，2019，4（1）：24-27.
[7]	林君，程书权，黄成军.干扰素在慢性乙型肝炎治疗中的应用[J].现代医药卫生，2018，34（24）：3745-3748，3752.
[8]	李晓飞.苦参素注射液联合重组人干扰素α-2b治疗84例HBeAg阳性慢性乙型肝炎的疗效观察[J].北方药学，2019，16（2）：94-95.
[9]	康倩锋.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药情况分析及其管理[J].首都食品与医药，2019，26（5）：59.
[10]	刘书宏，梁尘格，向毅，等.不同核苷（酸）类药物治疗乙型肝炎相关性肝癌患者成本效益分析[J].实用肝脏病杂志，2018，21（2）：293-294.
[11]	冯玥，霍璇，胡金芳，等.替芬泰对HepG2 细胞的线粒体毒性[J].中国药理学通报，2017，33（9）：1248-1252.
[12]	樊慧蓉，慈小燕，李薇，等.抗乙肝候选新药替芬泰的体外转运机制研究[J].药学学报，2016，51（8）：1233-1239.
[13]	Xu Y，Huang ZM，Xu BX，et al.Effect of phenylalaninedipeptide compounds 073 on duck hepatitis B virus[J].Clin J New Drug Clin Rem，2010，29（3）：217-220.
[15]	王宏亮，陈盼盼，何计龙.2010年版《中国药典》奈韦拉平有关物质检查存在问题的探讨[J].国际药学研究杂志，2015，42(4):524-526，530.
[16]	白楠，张杰，梅和坤，等.连续单剂静脉滴注乳酸卡德沙星在中国健康志愿者的耐受性及药代动力学[J].中国临床药理学杂志，2012，28（11）：809-812.
[14]	Meng FC，Xu WR，Li YZ，et al.In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase[J].Chin Herb Med，2015，7（1）：39-44.